# PROphylaxis for paTiEnts at Risk of COVID-19 infecTion -V

> **NCT04870333** · PHASE2,PHASE3 · COMPLETED · sponsor: **Cambridge University Hospitals NHS Foundation Trust** · enrollment: 2240 (actual)

## Conditions studied

- Covid19

## Interventions

- **DRUG:** Niclosamide
- **DRUG:** Placebo
- **DRUG:** Ciclesonide
- **DRUG:** Placebo
- **DRUG:** Sotrovimab
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT04870333
- **Lead sponsor:** Cambridge University Hospitals NHS Foundation Trust
- **Sponsor class:** OTHER
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-02-19
- **Primary completion:** 2025-04-16
- **Final completion:** 2025-04-16
- **Target enrollment:** 2240 (ACTUAL)
- **Last updated:** 2025-06-20

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04870333

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04870333, "PROphylaxis for paTiEnts at Risk of COVID-19 infecTion -V". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT04870333. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*